TSW
JAZZ icon

Thompson Siegel & Walmsley’s Jazz Pharmaceuticals JAZZ Stock Holding History

Thompson Siegel & Walmsley’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
5,045
-228,649
-98% -$50.1M 0.02% 315
2026
Q1 		$44.2M Sell
233,694
-56,506
-19% -$9.88M 0.77% 48
2025
Q4 		$49.3M Sell
290,200
-83,719
-22% -$12.8M 0.83% 40
2025
Q3 		$49.3M Sell
373,919
-200,903
-35% -$24.1M 0.8% 48
2025
Q2 		$61M Buy
574,822
+4,062
+0.7% +$441K 1.01% 29
2025
Q1 		$70.9M Sell
570,760
-130,162
-19% -$17M 1.19% 20
2024
Q4 		$86.3M Sell
700,922
-80,293
-10% -$9.46M 1.34% 9
2024
Q3 		$87M Buy
781,215
+59,685
+8% +$6.54M 1.3% 14
2024
Q2 		$77M Buy
721,530
+168,957
+31% +$18.6M 1.23% 19
2024
Q1 		$66.5M Buy
552,573
+200,011
+57% +$24.5M 1.02% 28
2023
Q4 		$43.4M Buy
352,562
+81,988
+30% +$10.2M 0.7% 53
2023
Q3 		$35M Buy
270,574
+191,648
+243% +$25.5M 0.58% 62
2023
Q2 		$9.78M Buy
78,926
+78,619
+25,609% +$10.6M 0.16% 140
2023
Q1 		$45K Hold
307
– – ﹤0.01% 429
2022
Q4 		$49K Hold
307
– – ﹤0.01% 420
2022
Q3 		$41K Hold
307
– – ﹤0.01% 429
2022
Q2 		$48K Hold
307
– – ﹤0.01% 420
2022
Q1 		$48K Sell
307
-148
-33% -$21.5K ﹤0.01% 463
2021
Q4 		$58K Sell
455
-12
-3% -$1.58K ﹤0.01% 469
2021
Q3 		$61K Sell
467
-13
-3% -$1.96K ﹤0.01% 460
2021
Q2 		$85K Buy
480
+105
+28% +$18.2K ﹤0.01% 445
2021
Q1 		$62K Sell
375
-248,930
-100% -$41M ﹤0.01% 454
2020
Q4 		$41.1M Buy
249,305
+17,027
+7% +$2.54M 0.66% 61
2020
Q3 		$33.1M Sell
232,278
-96,247
-29% -$11.9M 0.64% 55
2020
Q2 		$36.3M Buy
+328,525
New +$36.3M 0.73% 52
2020
Q1 		– Sell
-5
Closed -$1K – 715
2019
Q4 		$1K Buy
+5
New +$680 ﹤0.01% 751

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Thompson Siegel & Walmsley's JAZZ Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its Jazz Pharmaceuticals (JAZZ) stake by 98% in Q2 2026, selling an estimated $50.1M and leaving 5,045 shares worth $1.22M. The position accounts for 0.02% of the portfolio, ranked #315.

Thompson Siegel & Walmsley first reported a position in JAZZ in Q4 2019 and has held it in 26 quarters since. The position peaked at $87M in Q3 2024. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Thompson Siegel & Walmsley held 5,045 shares of Jazz Pharmaceuticals worth $1.22M as of Q2 2026.
  • Thompson Siegel & Walmsley sold 228,649 Jazz Pharmaceuticals shares in Q2 2026, an estimated $50.1M.
  • Jazz Pharmaceuticals made up 0.02% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #315 holding.
  • Thompson Siegel & Walmsley first reported a position in Jazz Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Thompson Siegel & Walmsley's Jazz Pharmaceuticals position peaked at $87M in Q3 2024.
  • 643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.